Pages that link to "Q28729034"

The following pages link to High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment (Q28729034):

Displaying 18 items.

• TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu (Q21131200) (← links)
• Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens (Q26774669) (← links)
• Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. (Q33679779) (← links)
• T cell avidity and tumor immunity: problems and solutions (Q34115960) (← links)
• Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8 (Q35724710) (← links)
• HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers (Q37622152) (← links)
• Heterogeneity assessment of functional T cell avidity. (Q37695291) (← links)
• CD4 T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8 T Cells (Q38839621) (← links)
• Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis (Q38869740) (← links)
• Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. (Q39043196) (← links)
• Target Density, Not Affinity or Avidity of Antigen Recognition, Determines Adoptive T Cell Therapy Outcomes in a Mouse Lymphoma Model. (Q40731929) (← links)
• SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade (Q41894814) (← links)
• Immunotherapy of WAP-TNP mice with early stage mammary gland tumors (Q41924363) (← links)
• SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors (Q41939949) (← links)
• Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes. (Q47564996) (← links)
• Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. (Q55235076) (← links)
• CD8 cytotoxic T cell responses to dominant tumor-associated antigens are profoundly weakened by aging yet subdominant responses retain functionality and expand in response to chemotherapy (Q64268788) (← links)
• Novel tumour antigens and the development of optimal vaccine design (Q89583558) (← links)